To address these gaps, future studies should standardize metabolic syndrome criteria (e.g., incorporating direct biomarkers such as insulin sensitivity), stratified analyses by antipsychotic class, dose, and illness chronicity, and integrate evidence-based behavioral strategies to enhance adherence. This evidence concerns the gene INS and metabolic syndrome.